Under terms of the agreement, the companies will work together to upscale the established Xcimzane manufacturing process and produce several commercial scale batches for upcoming phase I and phase III clinical trials as well as the Comparability Analytical Assessment required for regulatory filing.
'AGC is a high-quality partner with global manufacturing expertise, and we are pleased to enter into this agreement as the next step in the development of Xcimzane towards clinical trials,' says
Contact:
T: +46 8 588 941 51
(C) 2021 Electronic News Publishing, source